Diagnosis, family screening, and treatment of inherited arrhythmogenic diseases in Europe: results of the European Heart Rhythm Association Survey

Giulio Conte 1,2,3*, Daniel Scherr4, Radoslaw Lenarczyk5, Estelle Gandjbakhchh6, Stéphane Boulé7, Michael D. Spartalis8, Elijah R. Behr9,10 Arthur Wilde10,11, and Tatjana Potpara10,12,13

1Division of Cardiology, Cardiocentro Ticino, Lugano, Switzerland; 2Faculty of Biomedical Sciences, USI, Lugano, Switzerland; 3Centre for Computational Medicine in Cardiology, Faculty of Informatics, Università della Svizzeria Italiana, Lugano, Switzerland; 4Division of Cardiology, Medical University of Graz, Austria; 5First Department of Cardiology and Angiology, Silesian Centre for Heart Disease, Zabrze, Poland; 6Department of Cardiology, Sorbonne Universités, APHP, Cardiology Institute, ICAN, Pitié-Salpêtrière University Hospital, Paris, France; 7Department of Cardiology, Hôpital privé Le Bois, Lille, France; 8Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; 9Department of Cardiology, Cardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, London, UK; 10ERN GUARDHEART; 11Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands; 12School of Medicine, University of Belgrade, Belgrade, Serbia; and 13Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia

Received 15 June 2020; editorial decision 7 July 2020; accepted after revision 10 July 2020

Abstract

The spectrum of inherited arrhythmogenic diseases (IADs) includes disorders without overt structural abnormalities (i.e. primary inherited arrhythmia syndromes) and structural heart diseases (i.e. arrhythmogenic ventricular cardiomyopathy, hypertrophic cardiomyopathy). The aim of this European Heart Rhythm Association (EHRA) survey was to evaluate current clinical practice and adherence to 2015 European Society of Cardiology Guidelines regarding the management of patients with IADs. A 24-item centre-based online questionnaire was presented to the EHRA Research Network Centres and the European Cardiac Arrhythmia Genetics Focus Group members. There were 46 responses from 20 different countries. The survey revealed that 37% of centres did not have any dedicated unit focusing on patients with IADs. Provocative drug challenges were widely used to rule-out Brugada syndrome (BrS) (91% of centres), while they were used in a minority of centres during the diagnostic assessment of long-QT syndrome (11%), early repolarization syndrome (12%), or catecholaminergic polymorphic ventricular tachycardia (18%). While all centres advised family clinical screening with electrocardiograms for all first-degree family members of patients with IADs, genetic testing was advised in family members of probands with positive genetic testing by 33% of centres. Sudden cardiac death risk stratification was straightforward and in line with current guidelines for hypertrophic cardiomyopathy, while it was controversial for other diseases (i.e. BrS). Finally, indications for ventricular mapping and ablation procedures in BrS were variable and not in agreement with current guidelines in up to 54% of centres.

Keywords

Sudden cardiac death • Sudden cardiac arrest • Inherited arrhythmogenic diseases • Inherited primary arrhythmia syndromes • Cardiomyopathies • Genetic heart disease • EHRA survey

Introduction

The inherited arrhythmogenic diseases (IADs) are a heterogeneous group of genetic heart diseases predisposing to sudden cardiac arrest (SCA), including the primary inherited arrhythmia syndromes (IAS) and cardiomyopathies (CMPs). 1,2

The diagnostic approach to IADs is heterogeneous across European centres with regard to the use of provocative drug
challenges, genetic testing, and family screening of relatives. Risk prediction of sudden cardiac death (SCD) and indication to primary prevention using implantable cardioverter-defibrillator (ICD) still represent important unmet clinical needs for most of IADs.

In 2013 and 2015, European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC), together with its associated partners around the world defined specific recommendations on the diagnosis and treatment of IAS. In the following years, new therapeutic options have become more widely available, e.g., substrate ablation in BrS, which were only touched upon in the aforementioned documents.

The aim of this EHRA survey was to evaluate contemporary clinical practice in the management of patients with IADs, and adherence to the current 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD. The previous EHRA survey on IADs was conducted in 2014.

Methods and results

The EHRA Scientific Initiatives Committee conducted the present survey in collaboration with the European Cardiac Arrhythmia Genetics’ Focus Group (ECGen) and the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart). A centre-based online questionnaire was constructed to collect information about current diagnostic and therapeutic management of patients with IADs in Europe, including the following diseases: Brugada syndrome (BrS), long-QT syndrome (LQTS), short-QT syndrome (SQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), early repolarization syndrome (ERS), progressive cardiac conduction defect (PCCD), arrhythmogenic cardiomyopathy ( ACM), and hypertrophic cardiomyopathy (HCM). The link was sent out to the EHRA Research Network Centres and ECGen members. Of 54 centres answering the general questions about centre type, volume, and specialty, 46 centres (85.2%) completed the questionnaire and are included in this analysis. Hence, the results are reported as number and percentage of 46, unless otherwise specified (in case of missing response to a specific question, the total number of replies collected for that question is provided in the respective figure legend).

The 46 respondents represented centres from the following 20 countries: Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, Malta, The Netherlands, Portugal, Russian Federation, Serbia, Slovenia, Spain, Switzerland, Turkey, and Uzbekistan. Among participating centres, 70% were university hospitals, 17% non-university public hospitals, and 13% private hospitals/practice. Of the respondents, 85% had specific competences in cardiac electrophysiology, 15% in cardio-genetics, 6% in cardiac imaging, and 4% in paediatric cardiology or congenital heart diseases.

Half of all respondents declared the presence of dedicated units focusing on patients with IADs at their centre, while there were no specific IADs units in 37% of centres. In 13% of centres, there was a single dedicated unit for patients with IAS or CMPs.

Out of 46 centres, 14 (30%) managed >100 patients with IADs annually, 10 (22%) and 12 (26%) centres managed 50–100 patients with IAS and CMPs, respectively, and 25 (54%) and 24 (52%) centres managed <50 patients with IAS and CMPs, respectively. Moreover, there were 29 centres (63%) managing paediatric patients (<16 years) with IAS and CMPs, and 1 and 2 centres managing exclusively paediatric patients with IAS and CMPS, respectively.

Diagnostic assessment

All responding centres reported the use of baseline 12-lead electrocardiogram (ECG) as an important tool in the initial diagnostic evaluation of all suspected IAD cases. In case of a non-diagnostic baseline ECG, the most common indication to perform a pharmacological challenge was the presence of ECG abnormalities suggestive of IAS [e.g. Brugada type 2 ECG, malignant early repolarization pattern, borderline QTc, atrioventricular (AV) conduction disturbances] with or without syncope or aborted SCA (80%), followed by any aborted SCA of unknown aetiology (65%). Other indications for drug challenge included family history of SCD, family screening for IAS, atrial fibrillation (AF) in otherwise healthy subjects <50 years of age, sinus node dysfunction (SND) in patients <50 years of age, and any syncope/electrocardiographic changes in centre with unknown aetiology (<50 years of age). Provocative drug challenges were widely used to rule-out BrS (91% of centres), while they were used in a minority of centres for the diagnostic assessment of LQTS (11%), ERS (12%), or CPVT (18%).

Drug challenge was performed in a cardiac catheterization laboratory in 44% of centres, in cardiac intensive care unit in 24%, in the cardiology ward in 24%, and in outpatient clinic in the remaining 8% of centres. Ajmaline was the most commonly used drug to rule-out BrS (88% of centres), followed by flecainide (5%) or other drugs (i.e. propafenone, procainamide, 7%). A signal-averaged ECG was performed in BrS patients in 9% of centres, and in ACM patients in 37% of centres. The rate of diagnostic examinations performed in the assessment of different IAS and CMPs is shown in Figure 3.
Figure 2 Indications for pharmacological challenge. Total answers: 40. AF, atrial fibrillation; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SND, sinus node dysfunction.

Figure 3 Rate of diagnostic exams in patients with IADs. Total answers: BrS 46; CPVT 44; LQT 46; IVF 43; ACM 44; HCM 46. ACM, arrhythmogenic cardiomyopathy; BrS, Brugada syndrome; CMR, cardiac magnetic resonance; CPVT, catecholaminergic polymorphic ventricular tachycardia; HCM, hypertrophic cardiomyopathy; IAD, inherited arrhythmogenic disease; IVF, idiopathic ventricular fibrillation; LQT, long-QT syndrome.
The proportion of centres with and without dedicated IAS units undertaking genetic testing, according to the specific IAS or cardiomyopathy, is shown in Figure 4. Notably, centres with dedicated IAS units had a higher rate of genetic testing compared with centres without dedicated IAS units.

**Sudden cardiac death risk stratification**

The majority of centres (>73%) considered baseline 12-lead ECG findings as prognostic indicators in IADs, particularly for BrS, LQT, and ERS.

Electrophysiology study with programmed ventricular stimulation (PVS) was considered a tool for SCD risk stratification by 63% of centres for BrS, 33% for IVF, 24% for PCCD, 46% for ACM, and 17% for HCM. Only a minority of centres (10%) uses PVS for risk stratification purposes in patients with other IADs (CPVT, SQTS, ERS).

Specific indications to PVS in BrS are shown in Figure 5.

The majority of centres (96%) used a PVS protocol with two ventricular sites and up to three extrastimuli, while only 4% of centres less than three extrastimuli. Cardiac substrate invasive mapping data were used for SCD risk stratification in 5% of centres for BrS, 11% for IVF, and 15% for ACM. Genetic testing results were used for SCD risk stratification in 65% of centres for LQTS, 24% for BrS, 35% for CPVT, 28% for IVF, 16% for PCCD, 5% for ERS, 37% for ACM, and 46% for HCM. Cardiac magnetic resonance (CMR) was considered a risk stratification tool by 78% of centres for ACM and 73% for HCM. Importantly, all centres declared the use of the HCM risk-SCD calculator to estimate the risk of SCD at 5 years in all patients with HCM.

**Family screening**

All centres advised family clinical screening with ECGs of all first-degree family members of patients with IADs. Genetic testing was advised in first-degree relatives of a proband with a positive genetic testing by 33% of centres and only in symptomatic first-degree relatives by 2% of centres.

Sodium channel blocker challenge in paediatric BrS family members was considered by 67% while 33% of centres do not perform drug challenges in paediatric subjects due to concerns over potential pro-arrhythmic drug effects (Figure 6). Moreover, most centres (90%) recommended performing an ECG recording during fever in children with BrS or a family history of BrS.

**Therapeutic management**

In patients with IADs, 20% and 5% of centres considered implanting single-chamber and dual-chamber ICD, respectively. Subcutaneous ICD (S-ICD) was considered as a therapeutic option by 29% of centres if the sensing screening was appropriate and no anti-tachycardia pacing was expected. However, most centres (46%) determined the type of implantable electronic devices (transvenous vs. subcutaneous and single vs. dual-chamber) according to the specific disease and patient’s choice. The disease most commonly treated with S-ICD implantation, upon appropriate sensing screening, was
IVF (73%), followed by BrS (68%), and LQTS/ACM/HCM (54%/51%/44%). A minority of centres (17%) would not consider S-ICD implantation in IADs patients owing to concerns over the potential dynamic ECG changes and subsequent T-wave oversensing episodes. Most centres (64%) would utilize ventricular mapping and ablation procedures of arrhythmogenic substrate in BrS patients in the following conditions: ventricular arrhythmias recurrences/electrical storm in case of drug therapy failure (47%); ventricular arrhythmias recurrences/electrical storm as first choice (36%); and high-risk features (symptoms/ECG/ventricular arrhythmias inducibility at PVS) without ventricular arrhythmias recurrences/electrical storm (17%). The preferred procedural strategy adopted by most centres was endo-/epicardial mapping/ablation as the first approach for all cases (42%), followed by epicardial only mapping/ablation as the first approach (35%) and then endocardial only mapping/ablation as the first approach (19%). With regards to pharmacological therapy with quinidine, 72% of centres reported the availability of the drug in their country. In IADs patients with recurrent AF, an ablation procedure, instead of pharmacological rhythm control therapy, was preferred by most of the centres (93%). The preferred ablation strategy was pulmonary vein isolation (PVI) in 73% of centres, followed by PVI plus ablation of non-pulmonary vein triggers (27%).

Competitive athletes with inherited arrhythmogenic diseases and no implantable cardioverter-defibrillators

Most centres (96.2%) advised competitive sport avoidance in IADs patients without ICDs, most commonly for patients with CPVT (93%), ACM/HCM (88%), and LQTS-1 (71%). Up to 50% of centres would advise sport avoidance also in competitive athletes with LQT with unknown genotype, BrS, or ERS.

Discussion

The findings of this survey highlighted several features of the current management of IADs in participating European centres: (i) one in three centres had no dedicated unit for the management of patients with IADs; (ii) there was a considerable heterogeneity in indications for pharmacological challenge, genetic testing, family screening, and sport avoidance, (iii) genetic testing is more often performed in centres with dedicated IAS units; (iv) SCD risk stratification was in line with current guidelines for some (i.e. HCM), but still heterogeneous for other IADs (i.e. BrS), and (v) the indications for ventricular mapping and ablation procedures in BrS were variable and guideline non-adherent in 54% of centres.

Current guidelines do not address specific indications for drug challenges for many IADs. In our survey, provocative drug challenges were widely used to rule-out BrS (91% of centres), while they were used in a minority of centres (11–18%) for the diagnostic assessment of LQTS, CPVT, or ERS. Of note, despite the possibility that atrial arrhythmias and SND might be the first manifestation of an inherited electrical disorder especially in the young, only a few centres (15%) would perform a drug test to rule-out BrS. This may be due to concerns about the specificity of drug challenges that have arisen since the ESC guidelines were published (e.g. ajmaline challenge for BrS can...
have yields of almost 30% in patients with AV nodal re-entrant tachycardia). 9

As IVF is still considered a diagnosis of exclusion, an extensive diagnostic assessment should be performed in all unexplained SCA survivors to rule-out structural abnormalities or underlying IADs. 1 In our survey, CMR was used in the evaluation of unexplained SCA survivors by only 67% of centres. Interestingly, 26% and 51% of centres did not perform exercise stress testing and/or provocative drug challenge, respectively, to rule-out CPVT, BrS and LQTS in unexplained SCA survivors. It has been reported that up to 30% of the victims of swimming-related drowning had a cardiac ion channel mutation associated with LQT1 and CPVT; and that mutations associated with CPVT1, and to a lesser extent LQTS, are the most significant findings following post-mortem genetic testing in autopsy negative cases of SCD. 9,10

As these conditions are usually associated with catecholaminergic triggers of arrhythmic events, absence of exercise or provocative testing from the investigative protocol may lead to misdiagnosis in a proportion of SCA survivors.

In the 2013 HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of IAS, genetic testing was recommended for family members of a successfully genotyped proband. 1 Interestingly, in our survey, it was advised in first-degree relatives of a proband with a positive genetic testing by only 33% of centres. Notably, genetic testing was more commonly performed in centres with dedicated IAS units. With regard to family screening in BrS patients, one out of three centres did not perform sodium channel blocker challenge in paediatric BrS family members, owing to the concern over potential pro-arrhythmic drug effects, which is in line with published evidence. 6 For those centres performing drug challenge in children, the most common indication was the presence of symptoms, SND, atrial arrhythmias, or the family’s request. The ideal age for screening of BrS family members is unknown, and specific recommendations on screening are lacking, whereas limited supportive evidence suggests that postponing the screening until adult age is reasonable. 11 Indeed, children with BrS represent a category of patients at a higher risk of life-threatening arrhythmias during drug challenge and can have an age-dependent response to ajmaline. 6,12 This important issue should be specifically addressed in the future guidelines.

Current guidelines state that ICD implantation may be considered in patients with a diagnosis of BrS who develop VF during PVS with two or three extrastimuli at two sites (IIb/C recommendation). 2 Despite apparently limited utility of PVS in a pooled analysis of studies utilizing PVS in BrS patients, PVS was used more often in BrS patients when compared with the previous 2014 EHRA-SIC survey (39% vs. 63%). 3,13 Moreover, in the present survey, only a minority of centres (4%) used a less aggressive PVS protocol with <3 extrastimuli. Surprisingly, a minority of centres reported using electrophysiology study for SCD risk stratification in CPVT or LQTS despite the lack of any supportive guidelines or data for this approach.

According to guidelines, catheter ablation may be considered in patients with BrS and history of electrical storms or repeated appropriate ICD shocks (IIb/C). 2 In the 2014 EHRA-SIC survey, only 4% of centres declared ventricular ablation procedures, together with ICD implantation, as first-line therapy. In the present survey, 17% of centres would consider ablation procedures in high-risk BrS patients even in the absence of any documented spontaneous ventricular arrhythmias. In patients with recurrent arrhythmias, the proportion of centres regarding this as an indication for ablation procedures increased significantly over the last 6 years (from 8% to 56%). The more recent evidence for substrate ablation in BrS as well as the need for a randomized case–control study will likely be addressed in future guidelines. 4,5,13,14 Finally, although guidelines recommend competitive sport avoidance in patients with HCM, ACM, and CPVT, 7–12% of centres would not advise their patients accordingly. 2

Conclusions

Our survey suggests that the management of patients with IADs is heterogeneous across European centres with suboptimal adherence to current guidelines. Specific indications for drug challenges, genetic testing, ablation procedures, and family screening strategies are still unmet needs. This heterogeneity may reflect, in part, the absence of a dedicated unit for managing IAS patients. Further efforts to improve management of IADs across European countries are warranted.

Acknowledgements

The production of this document is under the responsibility of the Scientific Initiatives Committee of the European Heart Rhythm Association: Tatjana S. Potpara (Chair), Radoslaw Lenarczyk (Co-Chair), Giulio Conte, Gheorghe Andrei Dani, Michal M. Farkowski, Malcolm Finlay, Estelle Gandjbakhch, Konstantinos E. Iliodromitis, Kristine Jubele, Deirdre A. Lane, Eloi Marijon, Francisco Marin, Frits Prinzen, and Daniel Scherr. This work was also conducted in collaboration with the European Cardiac Arrhythmia Genetics’ Focus Group (ECGen) and the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart).

Conflict of interest: none declared.

References


